Vor Biopharma (NASDAQ:VOR) Upgraded at Baird R W

Key Points

• Vor Biopharma has been upgraded from a "hold" to a "strong-buy" rating by Baird R W, indicating positive investor sentiment.
• Stifel Nicolaus also upgraded the company's rating to "buy" with a price target of $55.00, reflecting increased confidence in the stock's performance.
• The company reported significant earnings losses of ($43.60) per share for the last quarter, missing analysts' expectations by over $32.00.

Vor Biopharma (NASDAQ:VOR - Get Free Report) was upgraded by investment analysts at Baird R W from a "hold" rating to a "strong-buy" rating in a research note issued on Wednesday,Zacks.com reports.

Other research analysts have also issued research reports about the company. Stifel Nicolaus raised Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price target on the stock in a research note on Wednesday, September 24th. Wall Street Zen lowered Vor Biopharma to a "strong sell" rating in a research note on Saturday, June 28th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Robert W. Baird upgraded Vor Biopharma from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $20.00 to $64.00 in a report on Wednesday. Finally, HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Vor Biopharma in a report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $77.83.

Vor Biopharma Stock Performance

NASDAQ VOR opened at $30.22 on Wednesday. Vor Biopharma has a fifty-two week low of $2.62 and a fifty-two week high of $65.80. The firm has a market capitalization of $207.13 million, a PE ratio of -0.11 and a beta of 2.07. The business has a fifty day moving average of $37.05.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Insider Buying and Selling at Vor Biopharma

In other news, major shareholder Reprogrammed Interchange Llc sold 33,668 shares of the firm's stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $30.32, for a total transaction of $1,020,813.76. Following the completion of the sale, the insider directly owned 1,278,118 shares in the company, valued at $38,752,537.76. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 1,117,860 shares of company stock worth $24,894,078 in the last three months. 0.45% of the stock is owned by company insiders.

Institutional Trading of Vor Biopharma

Large investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the second quarter valued at about $66,000. Money Concepts Capital Corp grew its stake in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Vor Biopharma during the first quarter valued at about $100,000. Finally, Jane Street Group LLC acquired a new stake in shares of Vor Biopharma during the first quarter valued at about $140,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.